Universitaire Ziekenhuizen KU Leuven
uzleuven.beLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
942
Active
266
Phase 3
27
Total enrollment
1,604,342
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Erythromycin | — | — | — | — | — | 2 | |
| Biological Drug | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | — | — | 1 | |
| Guselkumab | — | — | — | — | — | 1 | |
| Alginate | — | — | — | — | — | 1 | |
| STW 5-II | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| flecainide | — | — | — | — | — | 1 | |
| Sotalol or Amiodarone | — | — | — | — | — | 1 | |
| budesonide | — | — | — | — | — | 1 | |
| Mannitol | — | — | — | — | — | 1 | |
| Midazolam Mylan | — | — | — | — | — | 1 | |
| Lorazepam Mylan | — | — | — | — | — | 1 | |
| Valium + Akineton + Dehydrobenzperidol + Atropine sulfate | — | — | — | — | — | 1 | |
| Ursochol oral | — | — | — | — | — | 1 | |
| Buspirone Hydrochloride 10 MG | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | 2 | ||
| Androgen deprivation therapy | — | — | — | — | — | 1 | |
| Androgen receptor targeted therapy | — | — | — | — | — | 1 | |
| Semaglutide Pen Injector | — | — | — | — | — | 1 | |
| Semaglutide placebo | — | — | — | — | — | 1 | |
| Triptoreline | — | — | — | — | — | 1 | |
| Rikkunshi-to | — | — | — | — | — | 1 | |
| Rifaximin | — | — | — | — | — | 1 | |
| Letrozole | — | — | — | — | 3 | ||
| Abemaciclib | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | 2 | ||
| Doxorubicin | — | — | — | — | — | 1 | |
| ARN-509 | — | — | — | — | — | 1 | |
| Degarelix | — | — | — | — | — | 1 | |
| Bicalutamide | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Durvalumab + Tremelimumab | — | — | — | — | — | 1 | |
| zolbetuximab | — | — | — | — | — | 1 | |
| Vitamin E-creme | — | — | — | — | — | 1 | |
| [18F]AlF-OC | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Dostarlimab | — | — | — | — | — | 1 | |
| Zanidatamab Combined with Chemotherapy | — | — | — | — | — | 1 | |
| SOC | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2016-09
- 2021-07-01
- 2024-09-30
- 2025-01
- 2025-03
- 2025-03-24
- 2025-07
- 2025-07
- 2025-09
- 2025-10-29
Top conditions
- Breast Cancer22
- Healthy19
- Obesity16
- Functional Dyspepsia15
- Chronic Kidney Disease12
- Healthy Volunteers11
- Prostate Cancer10
- Coronary Artery Disease10
Frequently asked questions about Universitaire Ziekenhuizen KU Leuven
- How many clinical trials does Universitaire Ziekenhuizen KU Leuven have on ClinicalTrials.gov?
- Universitaire Ziekenhuizen KU Leuven is listed as the lead sponsor on 942 clinical trials in ClinicalTrials.gov, 266 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universitaire Ziekenhuizen KU Leuven's trials are in Phase 3?
- 27 of Universitaire Ziekenhuizen KU Leuven's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does Universitaire Ziekenhuizen KU Leuven focus on?
- Universitaire Ziekenhuizen KU Leuven's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Healthy, Obesity, Functional Dyspepsia, Chronic Kidney Disease.
- When are Universitaire Ziekenhuizen KU Leuven's next clinical trial readouts?
- Universitaire Ziekenhuizen KU Leuven has 10 upcoming primary-completion readouts tracked here; the soonest is “Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake”, expected around 2016-09.